Structural basis of a high-affinity antibody binding to glycoprotein region with consecutive glycosylation sites

Yunbin Han, Jun Niu, Deng Pan, Chunchao Feng, Ke Song, Bing Meng, Ulrika Westerlind, Yan Zhang, Haiguang Liu, Lan Xu, Dapeng ZhoubioRxiv 2022 · DOI

TL;DR

Researchers have uncovered the structural basis for how a high-affinity antibody (16A) binds to a specific peptide sequence (STAPPAHG) that is heavily decorated with sugar molecules (glycans). They found that a sugar modification at a threonine residue dramatically boosts the antibody's binding strength, revealing a crucial interaction mechanism that could inform the design of new cancer and viral vaccines.

What Problem Does This Paper Address?

Many important proteins, both in our own bodies and in viruses like HIV and SARS-CoV-2, are covered in a dense layer of sugar molecules called glycans. This "glycan shielding" is a double-edged sword: it helps protect our own cells from immune attack but also allows viruses to evade our immune system. Understanding how antibodies interact with these heavily glycosylated regions is crucial for developing effective vaccines and therapies. Specifically, the Mucin 1 (MUC1) protein, often overexpressed in cancer cells and aberrantly glycosylated, is a prime target for cancer immunotherapy. However, previous attempts to use unglycosylated MUC1 fragments as vaccines have been largely unsuccessful, likely due to differences in how the immune system recognizes the natural, glycosylated form. This paper aims to decipher the molecular details of how antibodies recognize MUC1 glycopeptide epitopes, focusing on the role of glycosylation in enhancing antibody binding affinity.

Methods

The researchers employed a multi-pronged approach:

  • Surface Plasmon Resonance (SPR): This technique was used to precisely measure the binding affinity (dissociation constants, KD) of antibody fragments (Fabs) to various synthetic peptides and glycopeptides. This allowed them to quantify the impact of different glycosylation patterns on binding strength.
  • X-ray Crystallography: They determined the 3D structures of antibody fragments (16A and 14A Fabs) in complex with their target peptides and glycopeptides. This provided atomic-level detail of how the antibody "grips" the antigen.
  • Molecular Dynamics (MD) Simulations: These simulations were used to model the dynamic interactions between the antibodies and glycopeptides over time, providing insights into the flexibility and stability of these interactions.
  • Mutagenesis: Specific amino acid residues in the antibody were altered to understand their role in binding and to dissect the contributions of different interaction types (e.g., hydrogen bonds, pi-stacking).
  • Flow Cytometry and Western Blotting: These techniques were used to assess antibody binding to intact cells and to confirm protein expression levels, respectively.

Datasets

The study utilized synthesized glycopeptides based on the MUC1 tandem repeat sequence (specifically, variants of RPAPGSTAPPAHG with different glycosylation patterns). These glycopeptides served as the antigens for antibody binding studies. The crystal structures of the antibody-glycopeptide complexes were deposited in the Protein Data Bank (PDB) with specific accession codes provided in the paper.

Key Insights and Ideas

  • Glycosylation as an Affinity Booster: The most striking finding is that the addition of a single N-acetylgalactosamine (GalNAc) sugar moiety to a threonine residue within the STAPPAHG peptide sequence dramatically increased the binding affinity of the 16A antibody by over 30-fold. This highlights how specific glycosylation can transform a weakly binding epitope into a high-affinity target.
  • Dual Interaction Mode: The antibody (16A) utilizes a groove-like binding site that accommodates the peptide backbone, but it also possesses a "glycan-binding edge." This edge specifically interacts with the proximal glycan, suggesting a sophisticated recognition mechanism that leverages both peptide and sugar information.
  • Specific Interactions Drive Affinity: The enhanced binding was attributed to specific interactions: hydrophilic and pi-stacking interactions between the GalNAc sugar on threonine and a tryptophan residue (Trp34) in the antibody's heavy chain CDR1 region. This detailed structural insight explains why the glycosylation is so impactful.
  • Threonine vs. Serine Glycosylation: The study revealed a significant preference for threonine glycosylation over serine glycosylation for antibody binding. While serine glycosylation had a minor effect, threonine glycosylation was a major driver of affinity enhancement.
  • Implications for Vaccine Design: The findings suggest that designing vaccines based on linear glycopeptides, particularly those with specific glycosylation patterns at key positions, could elicit stronger and more specific immune responses.

Key Results

  • The 16A antibody recognized the STAPPAHG peptide sequence.
  • GalNAc modification at the threonine residue of STAPPAHG increased the binding affinity of 16A Fab by 30.6-fold, resulting in a KD of 6.7 nM.
  • GalNAc modification at the serine residue had a much smaller effect on 16A binding.
  • Structural analysis revealed that the GalNAc on threonine forms favorable hydrophilic and pi-stacking interactions with Trp34 in the 16A antibody's heavy chain CDR1.
  • Mutating Trp34 in 16A to alanine or phenylalanine significantly reduced binding affinity and abolished the preference for the threonine-glycosylated peptide.
  • The study also characterized the binding of a related antibody, 14A, and found differences in its recognition of glycosylated peptides, particularly regarding serine glycosylation.

Limitations and Future Work

  • Limited Epitope Scope: The study focused on a specific MUC1 peptide sequence (STAPPAHG) and two antibodies (14A and 16A). While insightful, this may not represent the full diversity of MUC1 epitopes or antibody recognition modes.
  • In Vitro vs. In Vivo: The findings are based on in vitro studies using purified antibodies and synthetic peptides. Further in vivo studies are needed to confirm these interactions and their functional consequences in a biological context.
  • Future Directions: The authors suggest that their findings can guide the design of linear glycopeptide-based vaccines for cancer and viral diseases. Further research could explore other glycan modifications and their impact on antibody binding, as well as investigate the role of these interactions in autoimmune diseases where aberrant glycosylation is implicated. The identification of specific antibody-glycan interactions could also aid in the development of diagnostic tools.

Summary updated

Abstract

Abstract Consecutive glycosylation sites occur in both self and viral proteins. Glycan-shielding of underneath peptide region is a double-edged sword, that avoids immune attack to self-proteins, but helps viruses including HIV-1 and SARS-CoV2 to escape antibody binding. Here we report a high-affinity antibody, 16A, binding to linear peptide containing consecutive glycosylation sites. Co-crystallization of 16A Fab and glycopeptides with GalNAc modifications at different sites showed that STAPPAHG is the sequence recognized by 16A antibody. GalNAc modification at Threonine site on STAPPAHG sequence significantly increased the affinity of Fab binding by 30.6 fold (KD=6.7nM). The increased affinity is conferred by hydrophilic and pi-stacking interactions between the GalNAc residue on Threonine site and a Trp residue from the CDR1 region of the heavy chain. Furthermore, molecular modeling suggested that GalNAc on T site causes more favorable conformation for antibody binding. These results showed that glycan modification most proximal to linear peptide core epitope significantly increases antigenicity of a glycopeptide epitope. The antibody recognition mode by peptide-binding CDR groove with a glycan-binding edge, may shed light on designing of linear glycopeptide-based vaccines for cancer and viral diseases. Teaser A high-affinity antibody was found to bind densely glycosylated glycoprotein region by a peptide binding groove of the antibody’s variant region, with a glycan-binding edge specific to glycosylation site most proximal to core peptide epitope.
BibTeX
@misc{han2022structural,
  author = {Yunbin Han and Jun Niu and Deng Pan and Chunchao Feng and Ke Song and Bing Meng and Ulrika Westerlind and Yan Zhang and Haiguang Liu and Lan Xu and Dapeng Zhou},
  title = {{Structural basis of a high-affinity antibody binding to glycoprotein region with consecutive glycosylation sites}},
  year = {2022},
  doi = {10.1101/2022.07.24.501275},
  howpublished = {bioRxiv},
}
Figure